U.S., July 8 -- ClinicalTrials.gov registry received information related to the study (NCT07687914) titled 'A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma' on June 17.
Brief Summary: This is a Phase 2, open-label, multicenter,study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of IMM2510(Anti-PD-L1 and VEGF trap recombinant - Page 1 of 5 - protein) combine with IMM27M(Anti-CTLA-4 Humanized monoclonal antibody) in patients with advanced hepatocellular carcinoma who not have received the treatment for aHCC in past
Study Start Date: July 23
Study Type: INTERVENTIONAL
Condition:
HCC - Hepatocellular Carcinoma
Intervention:
DRUG: IMM2...